Lineage Bio (LCTX) - Utang jangka cendhak marang modal

The financial stability of Lineage Cell Therapeutics (LCTX) relies exclusively on capital raising, as consistent cash inflows are absent. The development of cell-based therapies involves massive innovation expenditures and stringent regulatory oversight. The current metric stands at 0.02. This price chart is available below, while the company's operations remain shielded from political turmoil due to its international medical status and partnerships in Europe and the US.

This metric assesses liquidity risk by measuring the proportion of short-term liabilities within the equity structure. For Lineage Cell Therapeutics (LCTX), this risk is mitigated by the macro-resilience of the biotechnology niche, where development depends on clinical success rather than market cycles. The indicator captures the company's sensitivity to the cost of debt and changes in regulatory rates. By analyzing the trend of loans with maturities of up to one year relative to equity, an investor can evaluate the business's financial autonomy.